Core Insights - Pfizer Inc. (NYSE:PFE) is perceived to trade more like a bond due to its 7% dividend yield, which has raised concerns about its stock performance despite a solid balance sheet and promising pipeline [2][3] - CEO Albert Bourla acknowledged the stock's undervaluation and addressed concerns regarding high tariffs, reliance on COVID revenue, and the company's strategy in the weight loss drug market [2] - The loss of exclusivity for Pfizer's drugs is a significant concern, and the company is actively working to mitigate this issue [2] Stock Performance - Jim Cramer expressed disbelief that Pfizer's stock remains at a 7% yield despite a strong quarterly performance and a robust balance sheet [3] - Cramer highlighted the disconnect between the company's performance and its stock price, indicating that the current valuation is "unfathomable" [3]

Core Points - Pfizer is committing to offer all prescription medications to Medicaid at the most favored nations pricing, which is expected to significantly reduce Medicaid costs [1] - The company will provide popular medications at discounts ranging from 50% to 100% for all consumers [2] - New medications introduced by Pfizer will also be sold at reduced most favored nation costs, aligning U.S. prices with those of other countries [4] - Pfizer plans to invest $70 billion to reshore domestic manufacturing facilities and fund research and development in the United States [4][5]